Document is current
Any future updates will be listed below
-
Authors
Lang-Stöberl, Anna https://orcid.org/0009-0005-3204-8943
Fabikan, Hannah
Hochmair, Maximilian
Kirchbacher, Klaus
Rodriguez, Vania Mikaela
Ay, Leyla
Weinlinger, Christoph
Rosenthaler, David
Illini, Oliver
Müser, Nino
Funk, Georg-Christian
Valipour, Arschang
-
Funding
Funding for this research was provided by:
Amgen
AstraZeneca
Bristol Myers Squibb
Boehringer Ingelheim
Eli Lilly Oncology
Gilead
Janssen
Merck
Merk Sharp&Dohme
Novartis
Pfizer
Roche
Sanofi
Takeda Oncology
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 15 March 2024
First Online: 23 April 2024
Declarations
:
: A.S. Lang-Stöberl, H. Fabikan, V.M. Rodriguez, C. Weinlinger and D. Rosenthaler declare that they have no competing interests. M. Hochmair reports personal fees for lectures, consultancy and participation in advisory boards from Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Lilly Oncology, Roche, MSD, Pfizer and Takeda Oncology. K. Kirchbacher reports personal fees for lectures, consultancy and participation in advisory boards from MSD, Astra Zeneca, Bristol-Myers Squibb, Roche, Pfizer, Sanofi, Boehringer Ingelheim. L. Ay reports personal fees for lectures and participation in advisory boards from Amgen, BMS, MSD, Roche, Sandoz and Astra Zeneca. O. Illini reports speaker fees and/or honoraria for advisory boards from Boehringer Ingelheim, Eli Lilly, Menarini, Merck Sharp & Dohme, Pfizer, and Roche and received research grants from Amgen outside of the submitted study. N. Müser reports personal fees for lectures, consultancy and participation in advisory boards from MSD, Roche, MEDCH. Additionally, registration fee, travel and accommodation from Sanofi, Astra Zeneca, Roche, Lilly Oncology. G.C. Funk reports personal fees for lectures, consultancy and participation in advisory boards from Eli Lilly, Astra Zeneca, Boehringer Ingelheim, Takeda, Pfizer, MSD, BMS, Novartis, Amgen, and Roche. A. Valipour reports personal fees for lectures, consultancy and participation in advisory boards from Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, and Menarini outside of the submitted study.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics committee of Vienna (EK-20-061-VK). Informed consent was obtained from all individual participants included in the study.
